Chapman et al. [23] showed by ELISA in 2007 that preoperative serum anti-p53 AAbs were present in 22/94 (23.4%) patients with newly diagnosed breast carcinoma and 6/40 (15%) patients with ductal carcinoma in situ. Here, TP53 is linked to breast carcinoma.